Prohibition Partners Psych reports..
Exclusive: Saint Vincent and the Grenadines announces initiative to permit psychedelic treatment and research
The Caribbean nation of Saint Vincent and the Grenadines has launched an initiative to permit and support psychedelic research and wellness. The initiative will begin as a Medicinal Wellness Feasibility Study, which is expected to last 24 to 30 months, and will include “cultivation, research, processing, and prescription of psychedelic plant-based compounds including psilocybin, ibogaine, peyote, ketamine, dimethyltryptamine, ayahuasca and sassafras,” according to a release made exclusively to PSYCH.
Much like Switzerland is an international destination for health spas, Saint Vincent and the Grenadines hopes to be a destination for psychedelic treatment. “St. Vincent and the Grenadines aspires to be a medicinal and wellness destination,” Ezra Ledger, Executive Director of the SVG Bureau of Standards, told PSYCH. “This Medicinal Wellness Feasibility Study is a bold-but-measured move toward this future aspiration. We intend to become one of the world’s premier options for safe and effective plant-based and psychedelic-assisted therapies and treatment.”
Read their full report at https://psych.prohibitionpartners.com/st-vincent-approves-psychedelics-programme/
